DE3650432D1 - Verfahren und Verwendung für ortspezifische Aktivierung von Substanzen. - Google Patents

Verfahren und Verwendung für ortspezifische Aktivierung von Substanzen.

Info

Publication number
DE3650432D1
DE3650432D1 DE3650432T DE3650432T DE3650432D1 DE 3650432 D1 DE3650432 D1 DE 3650432D1 DE 3650432 T DE3650432 T DE 3650432T DE 3650432 T DE3650432 T DE 3650432T DE 3650432 D1 DE3650432 D1 DE 3650432D1
Authority
DE
Germany
Prior art keywords
site
antibody
substances
specific activation
inactive substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3650432T
Other languages
English (en)
Other versions
DE3650432T2 (de
Inventor
Edgar Haber
Gary R Matsueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/689,851 external-priority patent/US5116613A/en
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of DE3650432D1 publication Critical patent/DE3650432D1/de
Application granted granted Critical
Publication of DE3650432T2 publication Critical patent/DE3650432T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3650432T 1985-01-08 1986-01-07 Verfahren und Verwendung für ortspezifische Aktivierung von Substanzen. Expired - Fee Related DE3650432T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/689,851 US5116613A (en) 1985-01-08 1985-01-08 Antibody-thrombolytic agent product and method of use
US77446985A 1985-09-10 1985-09-10

Publications (2)

Publication Number Publication Date
DE3650432D1 true DE3650432D1 (de) 1995-12-14
DE3650432T2 DE3650432T2 (de) 1996-04-18

Family

ID=27104496

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3650432T Expired - Fee Related DE3650432T2 (de) 1985-01-08 1986-01-07 Verfahren und Verwendung für ortspezifische Aktivierung von Substanzen.

Country Status (6)

Country Link
EP (1) EP0187658B1 (de)
JP (1) JP2573927B2 (de)
AT (1) ATE129901T1 (de)
AU (1) AU595173B2 (de)
DE (1) DE3650432T2 (de)
IL (1) IL77533A (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
US5716990A (en) * 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
EP0444158B1 (de) * 1988-11-18 1996-01-03 The Regents Of The University Of California Konjugierte polypeptide und verfahren zur herstellung und verwendung
DE69020548T2 (de) * 1989-04-03 1996-03-07 Centocor Inc Blutplättchenspezifische immunokonjugate.
DK176290D0 (da) * 1990-07-24 1990-07-24 Novo Nordisk As Terapeutisk og diagnostisk praeparat
JPH07501795A (ja) * 1991-10-01 1995-02-23 ザ・ジェネラル・ホスピタル・コーポレーション 活性化血小板表面に発現する活性化依存タンパク質とその抗体
US5961973A (en) 1992-03-06 1999-10-05 Crea; Roberto Pathogen-targeted biocatalysts
US5302707A (en) * 1992-03-26 1994-04-12 Affymax Technologies N.V. 5-fluorouridine nucleoside phosphate compounds
US5446132A (en) * 1992-10-01 1995-08-29 The General Hospital Corporation Thrombin-activated platelet protein-2 (TAPP-2)
EP0937146A2 (de) * 1996-09-20 1999-08-25 The General Hospital Corporation Zusammensetzung und verfahren zur verstärkung von fibrinolyse unter verwendung von antikörpern gegen alpha2-antiplasmin
GB0108332D0 (en) * 2001-04-03 2001-05-23 Univ Durham Lectin directed prodrug delivery system
EP1870345B1 (de) 2002-06-20 2010-10-13 Yoshino Kogyosho Co., Ltd. Beutelförmiger blasgeformter Behälter
WO2020103910A1 (en) * 2018-11-21 2020-05-28 Immunwork Inc. Polypeptide for treating pathological blood clots

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (de) * 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs
DE3482649D1 (de) * 1983-12-16 1990-08-09 Denis M Callewaert Stellenselektiver plasminogenaktivator und verfahren zu seiner herstellung und verwendung.

Also Published As

Publication number Publication date
EP0187658B1 (de) 1995-11-08
EP0187658A3 (en) 1988-09-07
EP0187658A2 (de) 1986-07-16
JPS61239889A (ja) 1986-10-25
ATE129901T1 (de) 1995-11-15
JP2573927B2 (ja) 1997-01-22
DE3650432T2 (de) 1996-04-18
AU595173B2 (en) 1990-03-29
AU5162285A (en) 1986-07-17
IL77533A (en) 1990-11-05

Similar Documents

Publication Publication Date Title
ATE129901T1 (de) Verfahren und verwendung für ortspezifische aktivierung von substanzen.
ES2075861T3 (es) Metodo y aparato para ensayos de quimioluminiscencia heterogeneos.
ES2068844T3 (es) Dispositivo analitico en fase solida y metodo para su utilizacion.
ES2039533T3 (es) Metodos y dispositivos para llevar a cabo ensayos de union especifica.
ATE67598T1 (de) Mit antigenen oder antikoerpern beschichteter traeger.
ATE228247T1 (de) Testreagentien und testvorrichtungen
DE68901632D1 (de) Reaktionsgefaess zur durchfuehrung von aufeinanderfolgenden analytischen testen.
EP0279097A3 (de) Teststreifen für Immunassay
DE3878820T2 (de) Vorrichtung fuer bindungstest.
DE3582405D1 (de) Bestimmung von chlamydia trachomatis.
ATE48037T1 (de) Verfahren und reagenz zur verwendung zur bestimmung von pivka-ii.
NO874453D0 (no) Fremgangsmaate til bestemmelse av anti-hiv, middel dertil og dets anvendelse i fremgangsmaaten.
DE69310667D1 (de) Immunoassayverfahren unter Anwendung photothermischer Strahlablenkungsspektroskopie
DE3485265D1 (de) Verfahren zur bestimmung eines polyvalenten antigens und reagenz hierfuer.
DE58907087D1 (de) Verfahren zur Bestimmung von für ein Antigen klassenspezifischen Antikörpern und dazu geeignetes Reagenz.
ES2054686T3 (es) Equipo de inmunoensayo.
ATE67597T1 (de) Verfahren und materialien zur durchfuehrung von spezifischen bindungstests.
DE69015253T2 (de) Immunassay von Elastase-1.
ATE128232T1 (de) Verfahren zur bestimmung von antigenen und/oder antikörpern in menschlichen körperflüssigkeiten sowie set zur durchführung des verfahrens.
ES2094115T3 (es) Inmunoensayo.
ATE42640T1 (de) Verfahren zum immobilisieren von substanzen an kunststoffestphasen und kunststoffestphasen zur verwendung in immunosorbentassays.
HUT53230A (en) Method for radioimmunological detecting prostaglandin e down 2 content

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee